|

Role of HbA1c in Predicting Adverse Pregnancy Outcomes

RECRUITINGSponsored by National University of Malaysia
Actively Recruiting
SponsorNational University of Malaysia
Started2024-06-27
Est. completion2026-06-26
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06676254

Summary

This study aims to determine the reference value of HbA1c that can be used to predict adverse pregnancy outcomes. These adverse outcomes include LGA fetus, shoulder dystocia, caesarean section, pre-term birth, pre-eclampsia and fetal neonatal hypoglycaemia.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Pregnant woman with singleton pregnancy
* Confirmed diagnosis of GDM based on Malaysia CPG (≥5.1/7.8)
* HbA1c level taken at least once at any time during the pregnancy
* Delivery after 28 weeks gestation

Exclusion Criteria:

* Major fetal anomaly
* Haemoglobin level of ≤9 g/dL (moderate or severe anaemia in pregnancy)
* Women with autoimmune diseases
* Overt diabetes or pre-existing diabetes

Conditions2

DiabetesGestational Diabetes

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.